{"0": {"lymphocytic leukemia": 0.6116964817047119, "chronic lymphocytic": 0.6005467176437378, "lymphocytic leukaemia": 0.6000722646713257, "leukemia hematology": 0.5208719372749329, "lymphocyte": 0.4776420593261719, "lymphocytic": 0.4706786870956421, "lymphocyte count": 0.46063512563705444, "leukemia": 0.4577649235725403, "follicular lymphoma": 0.45044395327568054, "lymphocytes": 0.44181835651397705, "small lymphocytic": 0.43497705459594727, "leukaemia": 0.428897500038147, "lymphoma": 0.40839236974716187, "patients with chronic": 0.40269458293914795, "enlarged lymph": 0.396618127822876, "swollen lymph": 0.38037896156311035, "hematologic malignancies": 0.3766985535621643, "lymph nodes": 0.3723773956298828, "lymph": 0.3701484799385071, "disease progression": 0.32878151535987854, "cell malignancies": 0.3281092345714569, "blood cancer": 0.3240678310394287, "blood cancers": 0.3194164037704468, "immunotherapy": 0.3193221092224121, "hematologist": 0.3186323642730713, "refractory chronic": 0.3169500231742859, "hematologist oncologist": 0.3147415220737457, "hematology": 0.3137839436531067, "disease": 0.304097443819046, "chronic": 0.2953049838542938, "tumor lysis": 0.2800779342651367, "cell therapy": 0.27999186515808105, "immune system": 0.265583336353302, "hematologic": 0.26352375745773315, "treatment naive": 0.26181721687316895, "monotherapy": 0.25935590267181396, "cancer therapy": 0.25793448090553284, "blood work": 0.25780579447746277, "white blood": 0.2522455155849457, "hematology advisor": 0.25053948163986206, "malignancies": 0.24946746230125427, "patients": 0.2455976903438568, "newly diagnosed": 0.24342522025108337, "younger patients": 0.23875008523464203, "cancer survivors": 0.23711079359054565, "targeted therapies": 0.23674175143241882, "venetoclax obinutuzumab": 0.23227369785308838, "chemotherapy free": 0.22906148433685303, "combination therapies": 0.22899529337882996, "was diagnosed": 0.22785553336143494}, "1": {"targeted therapy": 0.5208322405815125, "treatment paradigm": 0.5200909376144409, "targeted therapies": 0.4927923083305359, "combination therapy": 0.4913746416568756, "treatment options": 0.478557825088501, "cancer therapy": 0.464884877204895, "combination therapies": 0.4606311321258545, "treatment naive": 0.4452596604824066, "therapies": 0.43133535981178284, "treatments": 0.4296863079071045, "treatment": 0.4252699911594391, "therapeutics announces": 0.4240625500679016, "tg therapeutics": 0.41454407572746277, "therapy": 0.41314834356307983, "treatment landscape": 0.4084622859954834, "cell therapy": 0.40157726407051086, "therapeutics": 0.39252692461013794, "patients with chronic": 0.3901798725128174, "chemotherapy free": 0.3628261685371399, "monotherapy": 0.36034566164016724, "chemotherapy": 0.35555246472358704, "patients": 0.3530518114566803, "clinical trials": 0.3529994487762451, "clinical trial": 0.35141119360923767, "disease progression": 0.3442472815513611, "hematologist oncologist": 0.3431222140789032, "cll sll": 0.33150720596313477, "older patients": 0.33041203022003174, "therapeutic": 0.3288855254650116, "oncologist": 0.32876157760620117, "hematology advisor": 0.32310980558395386, "cure": 0.32185763120651245, "previously treated": 0.3208032250404358, "previously untreated": 0.31926220655441284, "immunotherapy": 0.3146344721317291, "clinical": 0.30887570977211, "cll": 0.3021709620952606, "younger patients": 0.2950490117073059, "cancer survivors": 0.2949477434158325, "treated": 0.2940937578678131, "untreated": 0.2940043807029724, "patient": 0.2888607978820801, "oncology": 0.28697723150253296, "hematologist": 0.28240031003952026, "elderly patients": 0.27719616889953613, "dr byrd": 0.2749798893928528, "dr abedin": 0.2672414183616638, "treating": 0.26144739985466003, "tumor lysis": 0.25113046169281006, "refractory cll": 0.25112998485565186}, "2": {"venetoclax obinutuzumab": 0.5757673978805542, "plus venetoclax": 0.5591245889663696, "venetoclax based": 0.5576299428939819, "venetoclax": 0.5131223797798157, "venclexta": 0.36143460869789124, "acalabrutinib demonstrates": 0.3478531241416931, "ibrutinib plus": 0.312090665102005, "acalabrutinib shows": 0.2928246855735779, "leukaemia": 0.28537479043006897, "acalabrutinib": 0.2828562557697296, "ibrutinib": 0.27921634912490845, "zanubrutinib": 0.27350255846977234, "refractory cll": 0.2733885645866394, "cll sll": 0.2706071734428406, "plus obinutuzumab": 0.2591674327850342, "cll": 0.25549226999282837, "btk inhibition": 0.2552206814289093, "bone marrow": 0.25489550828933716, "treatment naive": 0.2540404200553894, "previously untreated": 0.2511341869831085, "rituximab combo": 0.24885417520999908, "obinutuzumab combo": 0.2476010024547577, "combination therapy": 0.2461724877357483, "btk inhibitors": 0.242088183760643, "clinical trial": 0.24039386212825775, "leukemia": 0.23968033492565155, "combination therapies": 0.23570960760116577, "cirmtuzumab": 0.2345661222934723, "clinical trials": 0.23357245326042175, "btk inhibitor": 0.23215040564537048, "obinutuzumab": 0.2309451699256897, "umbralisib ublituximab": 0.22960105538368225, "previously treated": 0.2292269617319107, "clinical": 0.2113543599843979, "patients with chronic": 0.21110799908638, "cancer survivors": 0.21032482385635376, "cancer therapy": 0.2070821225643158, "plus rituximab": 0.2065410315990448, "treatments": 0.20643450319766998, "treatment paradigm": 0.20607683062553406, "lymphocytic leukaemia": 0.2019009292125702, "untreated": 0.2013695389032364, "treatment": 0.20123440027236938, "bone": 0.20030048489570618, "disease progression": 0.19977957010269165, "covid vaccine": 0.19762539863586426, "blood cancers": 0.1968419849872589, "ublituximab plus": 0.19662804901599884, "blood cancer": 0.19491985440254211, "leukemia hematology": 0.19373638927936554}, "3": {"ibrutinib plus": 0.5891596078872681, "acalabrutinib demonstrates": 0.5837371349334717, "ibrutinib": 0.5378904938697815, "acalabrutinib shows": 0.5232203006744385, "acalabrutinib": 0.49479252099990845, "zanubrutinib": 0.4407031238079071, "cll sll": 0.3892096281051636, "btk inhibition": 0.36295074224472046, "cll": 0.35878998041152954, "btk inhibitor": 0.3328089118003845, "btk inhibitors": 0.3326072692871094, "refractory cll": 0.32849156856536865, "venetoclax obinutuzumab": 0.3242839574813843, "umbralisib ublituximab": 0.3032025098800659, "plus venetoclax": 0.30168235301971436, "plus obinutuzumab": 0.29792463779449463, "ublituximab plus": 0.2975988984107971, "plus rituximab": 0.28314244747161865, "btk": 0.2712235450744629, "imbruvica": 0.26287615299224854, "rituximab combo": 0.2521771192550659, "dr barrientos": 0.24754127860069275, "bendamustine": 0.2434263825416565, "venetoclax based": 0.24164491891860962, "umbralisib": 0.23804664611816406, "ublituximab": 0.23797187209129333, "obinutuzumab combo": 0.23539933562278748, "obinutuzumab": 0.23347145318984985, "leukaemia": 0.22387707233428955, "dr abedin": 0.22272434830665588, "cell malignancies": 0.2166789472103119, "bone marrow": 0.2143251895904541, "rituximab": 0.21405255794525146, "cirmtuzumab": 0.21175789833068848, "dr mato": 0.21078145503997803, "venclexta": 0.2090047150850296, "duvelisib": 0.20511458814144135, "venetoclax": 0.2027716338634491, "more effective": 0.20193363726139069, "captivate trial": 0.20157882571220398, "plus fcr": 0.20011866092681885, "impact": 0.19928112626075745, "pi inhibitors": 0.19860780239105225, "malignancies": 0.19802522659301758, "my wbc": 0.19494110345840454, "wbc": 0.19308745861053467, "cancer survivors": 0.19200249016284943, "compared": 0.19142033159732819, "hematologic malignancies": 0.1859578788280487, "previously untreated": 0.183338463306427}, "4": {"cell therapy": 0.5635402202606201, "car cells": 0.4671177864074707, "cell transplant": 0.4488668441772461, "car cell": 0.44029080867767334, "cell malignancies": 0.4304209053516388, "targeted therapy": 0.4071628749370575, "targeted therapies": 0.39279335737228394, "cells": 0.3871757984161377, "cancer therapy": 0.36989814043045044, "chemotherapy free": 0.35579752922058105, "cell": 0.34224846959114075, "therapies": 0.33940279483795166, "combination therapy": 0.3294670581817627, "smudge cells": 0.3235809803009033, "lymphocyte count": 0.31942421197891235, "chemotherapy": 0.31795787811279297, "monotherapy": 0.3154473900794983, "therapy": 0.3136265277862549, "combination therapies": 0.3135799169540405, "tg therapeutics": 0.3125622868537903, "therapeutics announces": 0.3063041567802429, "lymphocytic leukaemia": 0.30595672130584717, "lymphocytic leukemia": 0.3021283745765686, "immunotherapy": 0.3018929958343506, "leukemia hematology": 0.2969866991043091, "lymphocytic": 0.29686859250068665, "lymphocyte": 0.29639875888824463, "therapeutics": 0.2963431477546692, "small lymphocytic": 0.29618746042251587, "treatments": 0.29571375250816345, "chronic lymphocytic": 0.2872738838195801, "treatment naive": 0.28622663021087646, "treatment": 0.2857138514518738, "therapeutic": 0.2833002805709839, "lymphocytes": 0.27841058373451233, "treatment paradigm": 0.278231143951416, "hematologist oncologist": 0.2711661458015442, "hematologic malignancies": 0.2692914605140686, "clinical trial": 0.2677033245563507, "cure": 0.2638174891471863, "clinical trials": 0.25989747047424316, "leukemia": 0.25569161772727966, "hematology advisor": 0.2539229393005371, "oncology": 0.2531692683696747, "leukaemia": 0.2518541216850281, "tumor lysis": 0.2518075108528137, "oncologist": 0.2516399323940277, "clinical": 0.2513044476509094, "car nk": 0.25062990188598633, "cel": 0.24977713823318481}, "5": {"cll sll": 0.5107874870300293, "cll": 0.452161580324173, "captivate trial": 0.434312641620636, "refractory cll": 0.3850474953651428, "captivate study": 0.38048022985458374, "dr byrd": 0.36953258514404297, "dr woyach": 0.35488012433052063, "clinical trial": 0.3454103469848633, "dr abedin": 0.340177446603775, "dr davids": 0.3336848020553589, "dr barrientos": 0.3324127495288849, "clinical trials": 0.3289104104042053, "dr mato": 0.3262562155723572, "dr wierda": 0.32595425844192505, "acalabrutinib demonstrates": 0.3135141432285309, "dr ghia": 0.3059574365615845, "phase trial": 0.3055635094642639, "trials": 0.3016003668308258, "dr": 0.2987114191055298, "trial": 0.2895120680332184, "phase study": 0.2890714406967163, "bone marrow": 0.28465306758880615, "dr danilov": 0.2843911945819855, "hematologist oncologist": 0.28064677119255066, "positive results": 0.27856194972991943, "results": 0.27657872438430786, "study shows": 0.27650943398475647, "oncologist": 0.27054956555366516, "zanubrutinib": 0.26013118028640747, "outcomes": 0.25558310747146606, "undetectable mrd": 0.25538429617881775, "covid vaccine": 0.25464481115341187, "acalabrutinib shows": 0.25229981541633606, "btk inhibition": 0.2504062056541443, "research": 0.24971279501914978, "plus fcr": 0.24925567209720612, "studies": 0.24325203895568848, "patients with chronic": 0.24085861444473267, "disease progression": 0.2357221245765686, "bendamustine": 0.23545247316360474, "clinical": 0.235329270362854, "oncology": 0.23462456464767456, "treatment paradigm": 0.2322934865951538, "targeted therapy": 0.22926217317581177, "cancer survivors": 0.22621716558933258, "ibrutinib plus": 0.2240186482667923, "combination therapy": 0.22343295812606812, "tg therapeutics": 0.22080469131469727, "venetoclax obinutuzumab": 0.22066627442836761, "side effects": 0.21977576613426208}, "6": {"cancer survivors": 0.5327409505844116, "blood cancers": 0.5076194405555725, "blood cancer": 0.5013381242752075, "covid vaccine": 0.497275173664093, "vaccines": 0.4789878726005554, "vaccine": 0.4710500240325928, "vaccination": 0.4682905375957489, "vaccinated": 0.4681329131126404, "cancer therapy": 0.4567088484764099, "cancers": 0.449030339717865, "fully vaccinated": 0.4468037486076355, "cancer": 0.4398875832557678, "cancer network": 0.42215538024902344, "immunotherapy": 0.421872079372406, "leukemia hematology": 0.3782669007778168, "chemotherapy free": 0.3711824417114258, "leukemia": 0.3614949584007263, "patients with chronic": 0.34233129024505615, "lymphocytic leukemia": 0.34213584661483765, "immune response": 0.3389136493206024, "hematologist oncologist": 0.333282470703125, "antibodies": 0.33231815695762634, "immune": 0.3294418454170227, "hematologic malignancies": 0.3251660466194153, "malignancies": 0.3251277208328247, "younger patients": 0.32460343837738037, "leukaemia": 0.3238556385040283, "lymphocytic leukaemia": 0.32267841696739197, "chemo": 0.3195275366306305, "patients": 0.31491905450820923, "hematologist": 0.31289079785346985, "cell malignancies": 0.3028942942619324, "lymphoma": 0.30178889632225037, "cancer center": 0.30111271142959595, "tumor lysis": 0.29853808879852295, "small lymphocytic": 0.2972792088985443, "blood work": 0.2961903512477875, "chemotherapy": 0.29570168256759644, "monotherapy": 0.2951134443283081, "chronic lymphocytic": 0.29246044158935547, "newly diagnosed": 0.28809410333633423, "immune system": 0.28471535444259644, "hematology": 0.28277748823165894, "disease": 0.2825324535369873, "oncologist": 0.28233593702316284, "disease progression": 0.28215065598487854, "lymphocyte count": 0.2770642638206482, "treatment naive": 0.2766340374946594, "enlarged lymph": 0.27227818965911865, "targeted therapies": 0.26853257417678833}, "7": {"older patients": 0.4311773478984833, "patients with chronic": 0.4272462725639343, "ibrutinib plus": 0.41091853380203247, "patients": 0.40489017963409424, "elderly patients": 0.3976192772388458, "ibrutinib": 0.38889673352241516, "acalabrutinib demonstrates": 0.38189056515693665, "younger patients": 0.37823486328125, "treatment naive": 0.3415118455886841, "patient": 0.3331994414329529, "zanubrutinib": 0.3328859210014343, "acalabrutinib shows": 0.3217223286628723, "btk inhibitors": 0.3209831118583679, "disease progression": 0.3178638815879822, "btk inhibitor": 0.3060998320579529, "btk inhibition": 0.30467987060546875, "acalabrutinib": 0.3011929392814636, "previously untreated": 0.29661208391189575, "untreated": 0.2940922975540161, "cll sll": 0.29023557901382446, "venetoclax obinutuzumab": 0.284760445356369, "treatments": 0.2838309109210968, "treatment paradigm": 0.2817937135696411, "treatment": 0.2806400656700134, "combination therapy": 0.27630549669265747, "dr abedin": 0.2754686772823334, "combination therapies": 0.2646782696247101, "disease": 0.2623414993286133, "cll": 0.26083940267562866, "hematologist oncologist": 0.2593831419944763, "hematologic malignancies": 0.2591027319431305, "hematologist": 0.25706514716148376, "clinical trials": 0.25684165954589844, "leukaemia": 0.2561701834201813, "leukemia hematology": 0.2500650882720947, "plus obinutuzumab": 0.2489473521709442, "previously treated": 0.24836775660514832, "clinical trial": 0.24544376134872437, "leukemia": 0.2444147914648056, "cancer survivors": 0.24275809526443481, "bone marrow": 0.24185416102409363, "venclexta": 0.24165640771389008, "plus venetoclax": 0.2405407428741455, "hematology advisor": 0.23757411539554596, "refractory cll": 0.23505434393882751, "cell malignancies": 0.2331678718328476, "tg therapeutics": 0.2283419817686081, "blood work": 0.22691382467746735, "treated": 0.22622695565223694, "venetoclax based": 0.22575828433036804}, "8": {"btk inhibitors": 0.6620519757270813, "btk inhibitor": 0.6531782150268555, "btk inhibition": 0.5987316966056824, "inhibitors": 0.530896782875061, "inhibitor": 0.5072770118713379, "pi inhibitors": 0.5018923282623291, "inhibition": 0.3798734247684479, "cell malignancies": 0.3396070897579193, "antibodies": 0.31621795892715454, "btk": 0.3154871463775635, "refractory cll": 0.3125842809677124, "ibrutinib plus": 0.31199997663497925, "cell therapy": 0.30084720253944397, "cll": 0.29504963755607605, "cll sll": 0.29442352056503296, "ibrutinib": 0.2917171120643616, "venetoclax obinutuzumab": 0.28477221727371216, "hematologic malignancies": 0.28447648882865906, "biosimilar": 0.28270792961120605, "targeted therapies": 0.2819613516330719, "combination therapy": 0.28011807799339294, "side effects": 0.2767391502857208, "dr abedin": 0.27517789602279663, "combination therapies": 0.2746545672416687, "targeted therapy": 0.27463942766189575, "antibody": 0.2715371251106262, "zanubrutinib": 0.269521027803421, "acalabrutinib demonstrates": 0.2643575668334961, "tg therapeutics": 0.26175570487976074, "cell transplant": 0.25092026591300964, "obinutuzumab": 0.2504817843437195, "plus obinutuzumab": 0.2498781383037567, "cells": 0.24835239350795746, "patients with chronic": 0.24779467284679413, "anti": 0.24675807356834412, "venclexta": 0.24615123867988586, "malignancies": 0.2443000078201294, "smudge cells": 0.2411053478717804, "treatment naive": 0.23934528231620789, "chemotherapy free": 0.238311767578125, "dr mato": 0.23800893127918243, "blood cancers": 0.23750144243240356, "cancer therapy": 0.23482319712638855, "umbralisib ublituximab": 0.23449523746967316, "prognostic factors": 0.23378701508045197, "blood cancer": 0.2291269153356552, "treatment paradigm": 0.2276148647069931, "chronic lymphocytic": 0.2270728051662445, "hematologist oncologist": 0.22640255093574524, "therapies": 0.2258642017841339}, "9": {"cancer therapy": 0.35646578669548035, "blood cancers": 0.34516286849975586, "lymphoma": 0.34464940428733826, "blood cancer": 0.3424447476863861, "leukemia": 0.32545214891433716, "cancer survivors": 0.32015183568000793, "tumor lysis": 0.31299275159835815, "cancer": 0.3122393488883972, "cancers": 0.30993175506591797, "hematologist oncologist": 0.3073423504829407, "lymph": 0.30630773305892944, "swollen lymph": 0.3028908371925354, "leukemia hematology": 0.29833295941352844, "newly diagnosed": 0.29532626271247864, "oncologist": 0.29439577460289, "leukaemia": 0.2908594310283661, "disease progression": 0.2840164601802826, "follicular lymphoma": 0.28349876403808594, "lymph nodes": 0.2830524444580078, "hematologist": 0.28253400325775146, "disease": 0.28207430243492126, "monotherapy": 0.28197360038757324, "patients": 0.28097739815711975, "lymphocytic leukemia": 0.2768150269985199, "tumor": 0.2766045928001404, "therapies": 0.2756451964378357, "diagnosis": 0.27338850498199463, "diagnosed": 0.273224413394928, "treatments": 0.27175670862197876, "was diagnosed": 0.2710150182247162, "lymphocyte count": 0.2704397439956665, "chemotherapy free": 0.26833170652389526, "immunotherapy": 0.26712650060653687, "lymphocytic leukaemia": 0.26475709676742554, "enlarged lymph": 0.26448559761047363, "patients with chronic": 0.2602649927139282, "chronic lymphocytic": 0.25511080026626587, "doctors": 0.2508845627307892, "cancer network": 0.2504400610923767, "older patients": 0.24915197491645813, "hematology advisor": 0.2487044334411621, "chemotherapy": 0.2485683411359787, "chemo": 0.2484726905822754, "treatment": 0.24765989184379578, "therapy": 0.24629324674606323, "lymphocyte": 0.24627524614334106, "combination therapies": 0.2459065020084381, "hematology": 0.2458954155445099, "younger patients": 0.24585309624671936, "clinical": 0.2457856386899948}, "10": {"patients with chronic": 0.4551663100719452, "patients": 0.3821532726287842, "disease progression": 0.3776875138282776, "older patients": 0.3541489243507385, "high risk": 0.34740227460861206, "cancer survivors": 0.33984291553497314, "disease": 0.3333964943885803, "tumor lysis": 0.3328667879104614, "younger patients": 0.32546985149383545, "hematologic malignancies": 0.32478660345077515, "patient": 0.32330912351608276, "leukemia hematology": 0.3192446827888489, "chronic lymphocytic": 0.3169533610343933, "cell malignancies": 0.3163822293281555, "malignancies": 0.31300845742225647, "infection": 0.3129422068595886, "risk": 0.3121889531612396, "fully vaccinated": 0.3111669421195984, "leukemia": 0.3111242949962616, "dr abedin": 0.31093043088912964, "enlarged lymph": 0.30778658390045166, "hematologist oncologist": 0.30680352449417114, "severe": 0.2997990846633911, "covid vaccine": 0.2956365942955017, "lymphocytic leukemia": 0.2941492795944214, "dr byrd": 0.2907077372074127, "vaccinated": 0.2906047999858856, "elderly patients": 0.29057538509368896, "lymphocytic leukaemia": 0.28916874527931213, "leukaemia": 0.28856950998306274, "lymphocyte count": 0.2831760346889496, "oncologist": 0.28203698992729187, "vaccination": 0.28126880526542664, "treatment naive": 0.28027305006980896, "dr wierda": 0.2792218327522278, "small lymphocytic": 0.2747560143470764, "blood cancer": 0.2735375165939331, "follicular lymphoma": 0.2730727195739746, "lymphoma": 0.27218174934387207, "syndrome": 0.2708965837955475, "blood cancers": 0.2698533236980438, "hematologist": 0.26769858598709106, "swollen lymph": 0.26533687114715576, "bone marrow": 0.26449811458587646, "vaccines": 0.2633204460144043, "dr woyach": 0.2596909999847412, "vaccine": 0.25915053486824036, "death": 0.2586010694503784, "dr": 0.2578203082084656, "refractory chronic": 0.25706946849823}, "11": {"prolongs pfs": 0.39316725730895996, "improves pfs": 0.38225996494293213, "acalabrutinib demonstrates": 0.366397500038147, "ibrutinib plus": 0.35868871212005615, "refractory cll": 0.3301534056663513, "umbralisib ublituximab": 0.31412020325660706, "ibrutinib": 0.3070273995399475, "pfs": 0.29902634024620056, "acalabrutinib shows": 0.29648059606552124, "btk inhibition": 0.2917312979698181, "relapsed refractory": 0.2870393991470337, "acalabrutinib": 0.2868923246860504, "btk inhibitor": 0.274946391582489, "btk inhibitors": 0.2728222906589508, "plus rituximab": 0.27198857069015503, "zanubrutinib": 0.26984143257141113, "ublituximab plus": 0.2676118314266205, "umbralisib": 0.26709508895874023, "plus obinutuzumab": 0.2577001452445984, "cll": 0.2548280656337738, "rituximab combo": 0.24074874818325043, "cll sll": 0.23570293188095093, "venetoclax obinutuzumab": 0.23317530751228333, "pi inhibitors": 0.2322615534067154, "btk": 0.22146514058113098, "previously untreated": 0.22143331170082092, "plus venetoclax": 0.2177661657333374, "plus fcr": 0.20932015776634216, "obinutuzumab combo": 0.20733055472373962, "venclexta": 0.20670382678508759, "rituximab": 0.20545542240142822, "ublituximab": 0.2053460031747818, "dr abedin": 0.20289838314056396, "refractory chronic": 0.2020946741104126, "more effective": 0.20056821405887604, "untreated": 0.1924852728843689, "obinutuzumab": 0.19042852520942688, "previously treated": 0.18996107578277588, "relapsed": 0.18143130838871002, "further": 0.18072840571403503, "disease progression": 0.18042951822280884, "improves": 0.17999029159545898, "treatment naive": 0.17887914180755615, "elevate tn": 0.17718926072120667, "better": 0.17692866921424866, "higher": 0.17609137296676636, "than": 0.17568305134773254, "less": 0.17485147714614868, "refractory": 0.1733408123254776, "dr barrientos": 0.1680392175912857}, "12": {"mutations": 0.5284532308578491, "mutation": 0.5031955242156982, "gene": 0.42968058586120605, "genetic": 0.3891462981700897, "cell malignancies": 0.34342342615127563, "disease progression": 0.3359246850013733, "biosimilar": 0.3127678632736206, "hematologic malignancies": 0.2850399911403656, "tumor lysis": 0.28231704235076904, "cell transplant": 0.28215479850769043, "leukemia hematology": 0.28028470277786255, "malignancies": 0.2620295286178589, "prognostic factors": 0.25804775953292847, "disease": 0.25582292675971985, "btk inhibition": 0.2480984628200531, "cancer survivors": 0.2427782118320465, "blood cancers": 0.24183982610702515, "oncology": 0.24144987761974335, "leukaemia": 0.2395838052034378, "cll sll": 0.23957735300064087, "hematologist oncologist": 0.23741436004638672, "leukemia": 0.23657304048538208, "cll": 0.23632626235485077, "chronic lymphocytic": 0.2325848937034607, "lymphocytic leukaemia": 0.22987353801727295, "lymphocytic leukemia": 0.22803592681884766, "blood cancer": 0.22750407457351685, "refractory cll": 0.22750182449817657, "hematologist": 0.2247459441423416, "syndrome": 0.22149837017059326, "btk inhibitors": 0.22126828134059906, "cancers": 0.22091823816299438, "follicular lymphoma": 0.2174311876296997, "immune response": 0.21705535054206848, "treatment paradigm": 0.21703636646270752, "bone marrow": 0.21667759120464325, "cells": 0.21658927202224731, "small lymphocytic": 0.2133180797100067, "hematology": 0.21279868483543396, "patients with chronic": 0.2104232907295227, "lymphocyte count": 0.20855794847011566, "btk inhibitor": 0.20472614467144012, "newly diagnosed": 0.20078235864639282, "tumor": 0.2004692256450653, "lymphocyte": 0.19986572861671448, "lymphocytic": 0.1985350400209427, "enlarged lymph": 0.1973404586315155, "chemo": 0.19661161303520203, "oncologist": 0.1952161192893982, "cancer": 0.1950477957725525}, "13": {"relapsed refractory": 0.6627751588821411, "refractory cll": 0.5403529405593872, "refractory chronic": 0.4755174517631531, "refractory": 0.4520438015460968, "relapsed": 0.39135420322418213, "btk inhibition": 0.3033660650253296, "pi inhibitors": 0.30105122923851013, "durable responses": 0.29069948196411133, "inhibition": 0.2826058864593506, "targeted therapy": 0.2774008810520172, "venclexta": 0.26821398735046387, "treatment naive": 0.2673744261264801, "inhibitor": 0.2638091742992401, "treatment paradigm": 0.2624967396259308, "btk inhibitor": 0.26069873571395874, "btk inhibitors": 0.2602444887161255, "targeted therapies": 0.2588268220424652, "response rate": 0.25715917348861694, "inhibitors": 0.2562316656112671, "cure": 0.2535499334335327, "immune response": 0.24596072733402252, "previously untreated": 0.24466221034526825, "untreated": 0.24306756258010864, "dr abedin": 0.2427285760641098, "resistance": 0.2405456155538559, "patients with chronic": 0.23667758703231812, "treatment options": 0.2365569770336151, "therapies": 0.23339998722076416, "treatment": 0.2317771017551422, "response rates": 0.23154428601264954, "tg therapeutics": 0.2304098755121231, "cancer therapy": 0.22990921139717102, "combination therapy": 0.22965013980865479, "disease progression": 0.22173452377319336, "tolerated": 0.22055090963840485, "cll sll": 0.21852552890777588, "cll": 0.21608415246009827, "again": 0.2146337628364563, "undetectable mrd": 0.21404601633548737, "treatments": 0.21364647150039673, "therapy": 0.2136000692844391, "chronic": 0.21161112189292908, "fatigue": 0.21133731305599213, "hematologist oncologist": 0.2106916904449463, "dr wierda": 0.2100771963596344, "combination therapies": 0.20977447926998138, "previously treated": 0.20545436441898346, "therapeutics announces": 0.2046419382095337, "captivate trial": 0.20166651904582977, "acalabrutinib demonstrates": 0.20019806921482086}, "14": {"cirmtuzumab": 0.42485684156417847, "mcl": 0.41909217834472656, "plus obinutuzumab": 0.40129053592681885, "obinutuzumab": 0.3820258378982544, "venetoclax obinutuzumab": 0.37482884526252747, "obinutuzumab combo": 0.371188759803772, "acalabrutinib demonstrates": 0.3659910559654236, "ibrutinib plus": 0.3399231731891632, "btk inhibitor": 0.3291047513484955, "btk inhibitors": 0.324569970369339, "acalabrutinib shows": 0.31242966651916504, "btk inhibition": 0.30865949392318726, "ibrutinib": 0.3037613034248352, "acalabrutinib": 0.288420706987381, "plus rituximab": 0.2691664695739746, "leukaemia": 0.2624697983264923, "ublituximab plus": 0.26227110624313354, "umbralisib ublituximab": 0.2610308527946472, "zanubrutinib": 0.2519450783729553, "lymphocytic leukaemia": 0.24738511443138123, "hematologic malignancies": 0.24560971558094025, "rituximab combo": 0.24538317322731018, "pi inhibitors": 0.23841243982315063, "ublituximab": 0.23146730661392212, "inhibitor": 0.23054549098014832, "enlarged lymph": 0.23052763938903809, "leukemia": 0.2261519879102707, "lymphocytic leukemia": 0.22549483180046082, "cll": 0.2247857004404068, "inhibitors": 0.22430425882339478, "plus venetoclax": 0.2215057909488678, "small lymphocytic": 0.22053872048854828, "chronic lymphocytic": 0.22027742862701416, "rituximab": 0.21965256333351135, "leukemia hematology": 0.2194737195968628, "cll sll": 0.21663935482501984, "follicular lymphoma": 0.2152235060930252, "lymphocyte count": 0.21284219622612, "patients with chronic": 0.21166372299194336, "immune response": 0.20922908186912537, "hematologist oncologist": 0.20873203873634338, "bone marrow": 0.20645380020141602, "dr abedin": 0.20630550384521484, "cell malignancies": 0.20530705153942108, "lymphocytic": 0.20352782309055328, "hematologist": 0.2028225064277649, "clinical trials": 0.20112499594688416, "umbralisib": 0.20054462552070618, "biosimilar": 0.19867725670337677, "lymphocyte": 0.1985296607017517}}